Newswise — February 23, 2015 – Patients receiving a brief intervention to help them quit smoking before surgery are still more likely to be nonsmokers at one-year follow-up, reports a study in Anesthesia & Analgesia.

The simple, inexpensive program triples the percentage of patients with long-term smoking cessation at one year after surgery, according to the study by Dr Susan M. Lee and colleagues of University of Western Ontario, London, Canada. They write, "Anesthesiologists and perioperative providers have a unique opportunity to help patients achieve both short-term and long-term smoking cessation." Brief Intervention Has Lasting Effect on Smoking CessationThe researchers performed a follow-up study of 168 patients from a previous randomized trial evaluating a "practical intervention" to help smokers quit before surgery. Three weeks before scheduled elective procedures, one group of patients received the smoking cessation program. The four-part programs consisted of brief counseling (less than five minutes) by a nurse, brochures on smoking cessation, referral to a quit-smoking hotline, and a free six-week supply of nicotine patches.

Patients in the control group received usual care. As reported last year in Anesthesia & Analgesia, about 14 percent of patients in the intervention group were confirmed as quitting smoking before surgery, compared to just four percent of the control group.

For the new study, Dr Lee and colleagues performed follow-up interviews with 127 of the patients. One year after surgery, 25 percent of patients in the intervention group said that they were no longer smoking, compared to eight percent in the comparison group. (The patient reports were not confirmed by testing in the follow-up study.)

On adjusted analysis, patients in the intervention group were three times more likely to be nonsmokers at one year. For every six patients enrolled in the program, one additional patient had achieved long-term smoking cessation. The effect remained significant even assuming that all patients lost to follow-up continued to smoke.

Patients with lower scores for nicotine dependence were six times more likely to be successful long-term quitters. None of 22 patients with chronic obstructive pulmonary disease, a lung disease usually caused by smoking, were able to achieve long-term cessation—although this wasn't a statistically significant predictor. Smoking history in "pack years" also didn't predict one-year smoking status. Surgery a 'Teachable Moment' to Help Smokers QuitPatients who smoke are at increased risk of surgical complications—particularly problems with wound healing and breathing-related complications. Anesthesiologists commonly evaluate patients before surgery, providing a chance to inform smokers about their excess risk, and to encourage them to stop smoking before their operation.

"Undergoing surgery can serve as a 'teachable moment' that may motivate patients to engage in permanent smoking cessation," Dr Lee and colleagues write. The original trial results found that the brief intervention increased the number of patients who quit smoking before surgery, at relatively low cost and without taking too much time away from doctors and nurses in busy preadmission clinics.

The new results show lasting benefits of the brief intervention, increasing patients' chances of being nonsmokers one year after surgery. Providing patients with nicotine patches to help them quit was a "vital component" of their program's success, Dr Lee and colleagues believe. They add, "Our study...may serve as a call to action for governments and health insurers to take advantage of the teachable moment, and support more widespread funding of drugs for smoking cessation therapy around the time of surgery."

Note: Dr Lee is now at University of California San Francisco.

Anesthesia & Analgesia is published by Wolters Kluwer Health.

Read the article in Anesthesia & Analgesia.

Article: "Long-Term Quit Rates After a Perioperative Smoking Cessation Randomized Controlled Trial" (doi: 10.1213/ANE.0000000000000555)


About Anesthesia & AnalgesiaAnesthesia & Analgesia was founded in 1922 and was issued bi-monthly until 1980, when it became a monthly publication. A&A is the leading journal for anesthesia clinicians and researchers and includes more than 500 articles annually in all areas related to anesthesia and analgesia, such as cardiovascular anesthesiology, patient safety, anesthetic pharmacology, and pain management. The journal is published on behalf of the IARS by Lippincott Williams & Wilkins (LWW), a division of Wolters Kluwer Health.

About the IARSThe International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia related practice; sponsors the SmartTots initiative in partnership with the FDA; supports the resident education initiative OpenAnesthesia; and publishes two journals, Anesthesia & Analgesia and A&A Case Reports.

About Wolters Kluwer HealthWolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America.maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Follow our official Twitter handle: @WKHealth.